Lori Leskin Speaks with The New York Times on New FDA Guidance for Social Media Use by Drug Companies
As Seen in The New York Times’ “FDA Proposes Rules for Listing Risks on Social Media”
The New York Times reports that the FDA issued a set of proposed rules on Tuesday that would require pharmaceutical and medical device companies to list the risks of their products in Twitter feeds if benefits are also mentioned. The rules would to other social media platforms that similarly limit message length. The guidelines also allow these industries to fix any information posted by third parties that could be seen as false or misleading.
According to Kaye Scholer Life Sciences Partner Lori Leskin, companies have hesitated to use Facebook and Twitter in the past due to uncertainty in the FDA rules and for fear of censure.
Also of Interest
- And Now A Word From The Panel: MDL Venue Choices November 30, 2016 • Articles
- Patrolmen’s Benevolent Association Honors Waks November 17, 2016 • Recognitions
- Second Circuit Expands Split on Nominative Fair Use November 16, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- Chambers UK 2017 Recognizes London Partners and Aviation Finance Practice November 7, 2016 • Recognitions
- Kaye Scholer Advises Biohaven on Oversubscribed Private Financing November 4, 2016 • Client Successes
- Lattanzio Receives NYSBA Pro Bono Award November 3, 2016 • Recognitions
- US News–Best Lawyers Recognizes 32 Kaye Scholer Practices and 41 Lawyers November 1, 2016 • Recognitions
- Kaye Scholer Succeeds on Behalf of Term Loan Lenders in Defeating Confirmation... October 31, 2016 • Client Successes